Senzime

The next-generation TetraGraph system was launched at the ANESTHESIOLOGY (ASA) 2024 conference held in the US on October 18th, 2024. The new TetraGraph is designed to help accelerate alignment to new clinical guidelines of quantitative train-of-four (TOF) monitoring with its proprietary Level-of-Block Gauge™, unique Adaptive Intelligence™ enabling precision-based monitoring, and a new 6th generation EMG algorithm with 4x higher resolution for unprecedented clinical accuracy.

“I am very satisfied with the launch at ASA and the positive response from US and international clinicians. The next-generation TetraGraph was highlighted in opening presentations consisting of leading anesthesiologists and ASA Task Force Members that led the recent publication of guidelines in favor of quantitative neuromuscular monitoring. This first order from Switzerland is a milestone and the start of an exciting commercial phase and I expect the new next-generation TetraGraph to reach new users and lead to continued growth in utilization rates”, comments Philip Siberg, CEO of Senzime.

Each year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing, making accurate monitoring during surgery essential for ensuring each patient receives the appropriate dose for a safe and timely recovery.

Senzime markets the TetraGraph portfolio including monitoring solutions used by anesthesiologists in thousands of operating rooms in leading hospitals worldwide. The proprietary technology meets the requirements of the recently published US and European clinical guidelines that is mandating anesthesiologists to use monitors to accurately determine the correct dose of neuromuscular blocking drugs and their antagonists and determine when patients have safely recovered post-surgery.